Clinical Studies

For more information about ResApp Health-sponsored clinical studies, please contact us at clinicalstudies@resapphealth.com.au.

Paediatric Clinical Studies

SMARTCOUGH-C Study

Purpose: A prospective study to evaluate the efficacy of the ResAppDx software application in diagnosis of pneumonia and other respiratory conditions (bronchiolitis, asthma, croup, upper or lower respiratory tract infections) in infants and children.

Details of this study are available at www.clinicaltrials.gov (NCT02973282).

Breathe-Easy Paediatric Study

Joondalup Health Campus, Perth, Australia
Princess Margaret Hospital, Perth, Australia
The University of Queensland, Brisbane, Australia

Purpose: Gather data from patients with a variety of respiratory conditions with the aim of further optimising the ResApp algorithms for pneumonia and asthma as well as broadening the validation to other common respiratory conditions such as bronchitis, bronchiolitis and upper respiratory tract conditions.

Inclusion criteria: Any child aged 0-10 years presenting to the Emergency Department of a participating institution with signs or symptoms of respiratory disease including cough, wheeze, stridor, increased work of breathing, cyanosis, additional auscultatory noises (crepitations) or low oximetry levels.

Exclusion criteria: Lack of a signed consent form or the need for ventilatory support (including non-invasive means such as CPAP, high flow nasal oxygen, BiPAP).

Result Releases:

June 22, 2017 ResApp Provides Updated Australian Paediatric Study Results
March 31, 2016 ResApp Provides Updated Paediatric Clinical Study Results
March 2, 2016 ResApp Achieves Breakthrough Performance in Paediatric Clinical Study
November 10, 2015 Further Positive Preliminary Results from Clinical Study
September 30, 2015 Positive preliminary results from current clinical study for diagnosing respiratory disease

Sardjito Study

Sardjito Hospital, Indonesia
The University of Queensland, Brisbane, Australia

The University of Queensland led a 91 patient clinical proof of concept peer-reviewed study at Sardjito Hospital, Gadjah Mada University in Indonesia. This study demonstrated that the platform was capable of classifying childhood pneumonia at a sensitivity greater than 90% and a specificity greater than 85% based on analysis of cough sound alone. By augmenting sound-based features with easily obtainable measurements, such as presence of fever and age, the university researchers were able to increase the specificity to above 95%. Using the same clinical study, the university documented that the platform could also accurately classify asthma. Results from this study have been published in peer-reviewed journals.

Adult Clinical Studies

Breathe-Easy Adult Study

Joondalup Health Campus, Perth, Australia
The Wesley Hospital, Brisbane, Australia
The University of Queensland, Brisbane, Australia

Purpose: Gather data from adults presenting to the ED with respiratory conditions such as upper respiratory tract infections, bronchitis, pneumonia, asthma and chronic obstructive pulmonary disease. The aim of the study is to demonstrate that ResApp’s technology, shown to be highly accurate for diagnosis of childhood respiratory conditions, can be extended to adults.

Inclusion criteria: Anyone aged over 10 years presenting to the Emergency Department of a participating institution with signs or symptoms of respiratory disease including cough, wheeze, stridor, increased work of breathing, cyanosis, additional auscultatory noises (crepitations) or low oximetry levels.

Exclusion criteria: Lack of a signed consent form or the need for ventilatory support (including non-invasive means such as CPAP, high flow nasal oxygen, BiPAP), terminal disease.

Result Releases:

October 3, 2016 ResApp Announces Further Positive Results from Adult Clinical Study
June 21, 2016 ResApp Announces Positive Preliminary Results from Adult Clinical Study
ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000

© 2017 ResApp Health Limited. All Rights Reserved.

CONTACT US

+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations

      

LEGAL

Terms of Use
Privacy Policy

ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States.

In the United States, ResAppDx is an investigational device and is not available for sale.